Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Aug;72(2):447–451. doi: 10.1038/bjc.1995.353

Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy.

E Zuckerman 1, E Toubi 1, T D Golan 1, T Rosenvald-Zuckerman 1, E Sabo 1, Z Shmuel 1, D Yeshurun 1
PMCID: PMC2034001  PMID: 7640230

Abstract

This study was undertaken to determine the prevalence of anti-cardiolipin antibodies (ACLAs) in patients with malignancy and to investigate a possible association of ACLAs with thromboembolic events in such patients. The study included 216 patients with solid and non-solid malignancies and an age-matched control group of 88 healthy subjects. ACLA levels were measured and related to thromboembolic phenomena (diagnosed by imaging methods) that occurred within 12 months of the diagnosis of cancer. Forty-seven patients (approximately 22%) with cancer were ACLA positive as compared with only three subjects (approximately 3%) in the control group (P < 0.0001). The ACLA-positive cancer patients had a significantly higher rate of thromboembolic events than ACLA-negative cancer patients: 13 of 47 (28%) vs 24 of 169 (14%), respectively (P < 0.05). High titres of either IgG-ACLA or IgM-ACLA were found in 10 out of 13 ACLA-positive cancer patients with thrombotic complications, but in only 2 out of 34 cancer ACLA-positive patients without thromboembolic events (P < 0.0001). In four cancer patients in whom ACLA levels were followed ACLA decreased after successful surgery/chemotherapy treatment and remained negative and thromboembolic free for 12 months of follow-up. Patients with malignancies show an increased prevalence of ACLA. Furthermore, ACLA-positive patients, mainly those with high titres, are much more prone to thromboembolic events.

Full text

PDF
447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Mondhiry H., McGarvey V. Tumor interaction with vascular endothelium. Haemostasis. 1987;17(5):245–253. doi: 10.1159/000215751. [DOI] [PubMed] [Google Scholar]
  2. Alarcón-Segovia D. Pathogenetic potential of antiphospholipid antibodies. J Rheumatol. 1988 Jun;15(6):890–893. [PubMed] [Google Scholar]
  3. Alarcón-Segovia D., Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol. 1989 Apr;16(4):482–488. [PubMed] [Google Scholar]
  4. Ambrus J. L., Ambrus C. M., Mink I. B., Pickren J. W. Causes of death in cancer patients. J Med. 1975;6(1):61–64. [PubMed] [Google Scholar]
  5. Asherson R. A., Block S., Houssiau F. A., Hughes G. R. Systemic lupus erythematosus and lymphoma: association with antiphospholipid syndrome. J Rheumatol. 1991 Feb;18(2):277–279. [PubMed] [Google Scholar]
  6. Asherson R. A., Khamashta M. A., Gil A., Vazquez J. J., Chan O., Baguley E., Hughes G. R. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989 Apr;86(4):391–399. doi: 10.1016/0002-9343(89)90335-5. [DOI] [PubMed] [Google Scholar]
  7. Asherson R. A., Khamashta M. A., Ordi-Ros J., Derksen R. H., Machin S. J., Barquinero J., Outt H. H., Harris E. N., Vilardell-Torres M., Hughes G. R. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989 Nov;68(6):366–374. [PubMed] [Google Scholar]
  8. Bastida E., Ordinas A. Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. Haemostasis. 1988;18(1):29–36. doi: 10.1159/000215780. [DOI] [PubMed] [Google Scholar]
  9. Bellotti V., Gamba G., Merlini G., Montani N., Bucciarelli E., Stoppini M., Ascari E. Study of three patients with monoclonal gammopathies and 'lupus-like' anticoagulants. Br J Haematol. 1989 Oct;73(2):221–227. doi: 10.1111/j.1365-2141.1989.tb00256.x. [DOI] [PubMed] [Google Scholar]
  10. Cariou R., Tobelem G., Soria C., Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med. 1986 May 1;314(18):1193–1194. doi: 10.1056/NEJM198605013141817. [DOI] [PubMed] [Google Scholar]
  11. Carreras L. O., Vermylen J. G. "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation. Thromb Haemost. 1982 Aug 24;48(1):38–40. [PubMed] [Google Scholar]
  12. Cervera R., Font J., López-Soto A., Casals F., Pallarés L., Bové A., Ingelmo M., Urbano-Márquez A. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis. 1990 Feb;49(2):109–113. doi: 10.1136/ard.49.2.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ciaudo M., Horellou M. H., Audouin J., De Carbonnieres C., Conard J., Samama M. Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: a report of four patients. Am J Hematol. 1991 Dec;38(4):271–276. doi: 10.1002/ajh.2830380404. [DOI] [PubMed] [Google Scholar]
  14. Conlan M. G., Haire W. D., Kessinger A., Armitage J. O. Prothrombotic hemostatic abnormalities in patients with refractory malignant lymphoma presenting for autologous stem cell transplantation. Bone Marrow Transplant. 1991 Jun;7(6):475–479. [PubMed] [Google Scholar]
  15. Donnér M., Békássy N. A., Garwicz S., Holmberg L., Wiebe T. Cerebral infarction in a girl who developed anticardiolipin syndrome after acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1992 Oct-Dec;9(4):377–379. doi: 10.3109/08880019209016611. [DOI] [PubMed] [Google Scholar]
  16. Duncombe A. S., Dalton R. G., Savidge G. F. Lupus-type coagulation inhibitor in hairy cell leukaemia and resolution with splenectomy. Br J Haematol. 1987 Jan;65(1):120–121. doi: 10.1111/j.1365-2141.1987.tb06149.x. [DOI] [PubMed] [Google Scholar]
  17. Dührsen U., Paar D., Kölbel C., Boekstegers A., Metz-Kurschel U., Wagner R., Kirch W., Meusers P., König E., Brittinger G. Lupus anticoagulant associated syndrome in benign and malignant systemic disease--analysis of ten observations. Klin Wochenschr. 1987 Sep 15;65(18):852–859. doi: 10.1007/BF01737004. [DOI] [PubMed] [Google Scholar]
  18. Font J., Cervera R., Lopez-Soto A., Pallares L., Bosch X., Ampurdanes S., Casals F. J., Ingelmo M. Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations. Clin Rheumatol. 1989 Dec;8(4):475–483. doi: 10.1007/BF02032099. [DOI] [PubMed] [Google Scholar]
  19. Font J., López-Soto A., Cervera R., Balasch J., Pallarés L., Navarro M., Bosch X., Ingelmo M. The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity. 1991;9(1):69–75. doi: 10.3109/08916939108997126. [DOI] [PubMed] [Google Scholar]
  20. Glaspy J. A. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am. 1992 Dec;6(6):1301–1314. [PubMed] [Google Scholar]
  21. Goldberg R. J., Seneff M., Gore J. M., Anderson F. A., Jr, Greene H. L., Wheeler H. B., Dalen J. E. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med. 1987 Feb;147(2):251–253. [PubMed] [Google Scholar]
  22. Goldenberg G. J., Paraskevas F., Israels L. G. The association of rheumatoid arthritis with plasma cell and lymphocytic neoplasms. Arthritis Rheum. 1969 Dec;12(6):569–579. doi: 10.1002/art.1780120604. [DOI] [PubMed] [Google Scholar]
  23. Gordon S. G., Franks J. J., Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res. 1975 Feb;6(2):127–137. doi: 10.1016/0049-3848(75)90018-3. [DOI] [PubMed] [Google Scholar]
  24. Greenlee J. E., Brashear H. R. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol. 1983 Dec;14(6):609–613. doi: 10.1002/ana.410140603. [DOI] [PubMed] [Google Scholar]
  25. Gruber M. L., Hochberg F. H. Visual scotomata resulting from lupus anticoagulant in a patient with lymphoma in remission. J Neurooncol. 1991 Dec;11(3):255–257. doi: 10.1007/BF00165534. [DOI] [PubMed] [Google Scholar]
  26. Harris E. N., Gharavi A. E., Asherson R. A., Boey M. L., Hughes G. R. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol. 1984 Jan-Mar;2(1):47–51. [PubMed] [Google Scholar]
  27. Harris E. N., Gharavi A. E., Patel S. P., Hughes G. R. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987 Apr;68(1):215–222. [PMC free article] [PubMed] [Google Scholar]
  28. Hughes G. R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1088–1089. doi: 10.1136/bmj.287.6399.1088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kozlowski C. L., Johnson M. J., Gorst D. W., Willey R. F. Lung cancer, immune thrombocytopenia and the lupus inhibitor. Postgrad Med J. 1987 Sep;63(743):793–795. doi: 10.1136/pgmj.63.743.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lang B., Newsom-Davis J., Wray D., Vincent A., Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981 Aug 1;2(8240):224–226. doi: 10.1016/s0140-6736(81)90474-8. [DOI] [PubMed] [Google Scholar]
  31. Legrand I., Lalande G., Neuenschwander S., Dulac O., Kalifa L. G. Thrombose du sinus longitudinal supérieur au cours du traitement de lymphome chez l'enfant. Quatre observations. J Radiol. 1986 Aug-Sep;67(8-9):595–600. [PubMed] [Google Scholar]
  32. Levine M. N., Gent M., Hirsh J., Arnold A., Goodyear M. D., Hryniuk W., De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988 Feb 18;318(7):404–407. doi: 10.1056/NEJM198802183180703. [DOI] [PubMed] [Google Scholar]
  33. Levine S. R., Diaczok I. M., Deegan M. J., Kieran S. N., Feit H., Elias S. B., Welch K. M. Recurrent stroke associated with thymoma and anticardiolipin antibodies. Arch Neurol. 1987 Jun;44(6):678–679. doi: 10.1001/archneur.1987.00520180090026. [DOI] [PubMed] [Google Scholar]
  34. Levine S. R., Welch K. M. The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol. 1987 Aug;44(8):876–883. doi: 10.1001/archneur.1987.00520200078024. [DOI] [PubMed] [Google Scholar]
  35. Makar A. P., Vanderheyden J. S., Verheyen A. Maternal and fetal complications associating lupus anticoagulant and its management; three case reports. Eur J Obstet Gynecol Reprod Biol. 1990 Jul-Aug;36(1-2):185–195. doi: 10.1016/0028-2243(90)90066-a. [DOI] [PubMed] [Google Scholar]
  36. Meyrier A., Becquemont L., Weill B., Callard P., Rainfray M. Hemolytic-uremic syndrome with anticardiolipin antibodies revealing paraneoplastic systemic scleroderma. Nephron. 1991;59(3):493–496. doi: 10.1159/000186616. [DOI] [PubMed] [Google Scholar]
  37. Miller D. G. The association of immune disease and malignant lymphoma. Ann Intern Med. 1967 Mar;66(3):507–521. doi: 10.7326/0003-4819-66-3-507. [DOI] [PubMed] [Google Scholar]
  38. Mills R. C., Zacharski L. R., McIntyre O. R. Case report: circulating anticoagulant, autoimmune hemolytic anemia and malignant lymphoma. Am J Med Sci. 1977 Jul-Aug;274(1):75–81. doi: 10.1097/00000441-197707000-00011. [DOI] [PubMed] [Google Scholar]
  39. Montalbán J., Codina A., Ordi J., Vilardell M., Khamashta M. A., Hughes G. R. Antiphospholipid antibodies in cerebral ischemia. Stroke. 1991 Jun;22(6):750–753. doi: 10.1161/01.str.22.6.750. [DOI] [PubMed] [Google Scholar]
  40. Naschitz J. E., Yeshurun D., Lev L. M. Thromboembolism in cancer. Changing trends. Cancer. 1993 Feb 15;71(4):1384–1390. doi: 10.1002/1097-0142(19930215)71:4<1384::aid-cncr2820710433>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  41. Rickles F. R., Edwards R. L., Barb C., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer. 1983 Jan 15;51(2):301–307. doi: 10.1002/1097-0142(19830115)51:2<301::aid-cncr2820510223>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  42. Rivier G., Herranz M. T., Khamashta M. A., Hughes G. R. Thrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments. Lupus. 1994 Apr;3(2):85–90. doi: 10.1177/096120339400300205. [DOI] [PubMed] [Google Scholar]
  43. Sack G. H., Jr, Levin J., Bell W. R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977 Jan;56(1):1–37. [PubMed] [Google Scholar]
  44. Schleider M. A., Nachman R. L., Jaffe E. A., Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976 Oct;48(4):499–509. [PubMed] [Google Scholar]
  45. Schreiber D. P., Kapp D. S. Axillary-subclavian vein thrombosis following combination chemotherapy and radiation therapy in lymphoma. Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):391–395. doi: 10.1016/0360-3016(86)90356-1. [DOI] [PubMed] [Google Scholar]
  46. Shaukat M. N., Hughes P. Recurrent thrombosis and anticardiolipin antibodies associated with adenocarcinoma of the lung. Postgrad Med J. 1990 Apr;66(774):316–318. doi: 10.1136/pgmj.66.774.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Thiagarajan P., Shapiro S. S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980 Sep;66(3):397–405. doi: 10.1172/JCI109869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Warren B. A., Vales O. The adhesion of thromboplastic tumour emboli to vessel walls in vivo. Br J Exp Pathol. 1972 Jun;53(3):301–313. [PMC free article] [PubMed] [Google Scholar]
  49. Watts R. A., Williams W., Le Page S., Norden A., Soltys A., Swana G., Addison I., Hay F. C., Isenberg D. A. Analysis of autoantibody reactivity and common idiotype PR4 expression of myeloma proteins. J Autoimmun. 1989 Oct;2(5):689–700. doi: 10.1016/s0896-8411(89)80007-1. [DOI] [PubMed] [Google Scholar]
  50. Wisløff F., Sletnes K. E., Michaelsen T. Shared idiotypic determinant in mono- and polyclonal anti-phospholipid antibodies with lupus anticoagulant activity. Thromb Res. 1991 Feb 1;61(3):201–211. doi: 10.1016/0049-3848(91)90096-f. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES